BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

Q1 Revenue Rises But Many New Drugs Disappoint

 
• By Mandy Jackson

Revlimid and Eliquis beat expectations in the first quarter, but the products have dwindling exclusivity, making new drugs the main focus for Bristol. So the company will reinvest cost savings in R&D.

Budget cuts. Inflation threatens savings. Loss of savings and investments.
Cost reductions will result in 2,200 job cuts • Source: Shutterstock

More from Business

More from Scrip